Who are Conventional Vincristine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Adcetris, Halaven, Jevtana Kit, Taxol, Taxol, Standard of Care: Docetaxel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/conventional-vincristine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Conventional Vincristine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Conventional Vincristine (Conventional Vincristine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vinca alkaloid. Area: Oncology.

phase 3 Vinca alkaloid Tubulin Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Conventional Vincristine (Conventional Vincristine) — Universität des Saarlandes. Vincristine is a vinca alkaloid that binds to tubulin and disrupts microtubule formation, causing cell cycle arrest in metaphase and triggering apoptosis in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Conventional Vincristine TARGET	Conventional Vincristine	Universität des Saarlandes	phase 3	Vinca alkaloid	Tubulin
Adcetris	brentuximab-vedotin	Pfizer	marketed	CD30-directed Immunoconjugate [EPC]	Tubulin beta	2011-01-01
Halaven	ERIBULIN	Eisai	marketed	Microtubule Inhibitor	Tubulin beta	2010-01-01
Jevtana Kit	cabazitaxel	Accord Hlthcare	marketed	Microtubule Inhibitor	Tubulin beta	2010-01-01
Taxol	paclitaxel	Pfizer	marketed	Microtubule Inhibitor [EPC]	Tubulin beta-3 chain	1992-01-01
Taxol	nab-paclitaxel	Pfizer	marketed	Microtubule Inhibitor	Tubulin beta-3 chain	1992-01-01
Standard of Care: Docetaxel	Standard of Care: Docetaxel	H. Lee Moffitt Cancer Center and Research Institute	marketed	Taxane; microtubule stabilizer	β-tubulin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-06-10 — Jevtana Kit · 7241907*PED · Compound · US
2026-08-13 — Taxol · 8034375 · Method of Use · US
2026-08-13 — Taxol · 8034375 · US
2026-08-21 — Taxol · 9101543*PED · US
2026-08-21 — Taxol · 8268348*PED · Compound · US
2026-08-21 — Taxol · 7758891*PED · Compound · US
2026-08-21 — Taxol · 9101543*PED · Compound · US
2026-08-21 — Taxol · 8268348*PED · US
2026-08-21 — Taxol · 7758891*PED · US
2027-02-13 — Taxol · 8034375*PED · Compound · US
2027-02-13 — Taxol · 8034375*PED · US
2030-10-27 — Jevtana Kit · 12453712 · Method of Use · US
2030-10-27 — Jevtana Kit · 10583110 · Method of Use · US
2030-10-27 — Jevtana Kit · 10716777 · Method of Use · US
2030-10-27 — Jevtana Kit · 8927592 · Method of Use · US
2031-04-27 — Jevtana Kit · 12453712*PED · Compound · US
2031-04-27 — Jevtana Kit · 8927592*PED · Compound · US
2031-04-27 — Jevtana Kit · 10583110*PED · Compound · US
2031-04-27 — Jevtana Kit · 10716777*PED · Compound · US
2032-03-04 — Taxol · 9393318 · Method of Use · US
2032-03-04 — Taxol · 9597409 · US
2032-03-04 — Taxol · 9393318 · US
2032-03-04 — Taxol · 9597409 · Method of Use · US
2032-09-04 — Taxol · 9393318*PED · Compound · US
2032-09-04 — Taxol · 9597409*PED · Compound · US
2032-09-04 — Taxol · 9393318*PED · US
2032-09-04 — Taxol · 9597409*PED · US
2034-01-12 — Taxol · 9511046 · US
2034-01-12 — Taxol · 9511046 · Method of Use · US
2034-07-12 — Taxol · 9511046*PED · US

Sponsor landscape (Vinca alkaloid class)

Assistance Publique Hopitaux De Marseille · 1 drug in this class
Spectrum Pharmaceuticals, Inc · 1 drug in this class
Universität des Saarlandes · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Conventional Vincristine — Competitive Intelligence Brief. https://druglandscape.com/ci/conventional-vincristine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing